Spots Global Cancer Trial Database for pd1 antibody
Every month we try and update this database with for pd1 antibody cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| A Phase I Clinical Study for Evaluating the Safety of MASCT-I in Advanced Soild Tumor | NCT03393416 | Advanced Gastri... | MASCT-I PD1 antibody | 18 Years - 70 Years | HRYZ Biotech Co. | |
| Anti-PD1 Antibody Toripalimab Combined With Gemox as First-line Therapy in Late-stage Intrahepatic Cholangiocarcinoma | NCT04961788 | Intrahepatic Ch... | Gemox combimed ... | 18 Years - 75 Years | Shanghai Zhongshan Hospital | |
| Phase II-III Clinical Trial of PD1 Antibody (Toripalimab), Lenvatinib and GEMOX Neoadjuvant Treatment for Resectable Intrahepatic Cholangiocarcinoma With High-risk Recurrence Factors | NCT04669496 | Intrahepatic Ch... PD1 Antibody Lenvatinib Gemox Chemother... | Neoadjuvant tre... | 18 Years - 70 Years | Shanghai Zhongshan Hospital | |
| CLDN6/GPC3/Mesothelin/AXL-CAR-NK Cell Therapy for Advanced Solid Tumors | NCT05410717 | Stage IV Ovaria... Testis Cancer, ... Endometrial Can... CAR NK | Claudin6, GPC3,... | 18 Years - 75 Years | Second Affiliated Hospital of Guangzhou Medical University | |
| PD1 Antibody and Lenalidomide as a Treatment for EBV-HLH or CAEBV | NCT04084626 | EBV Infection | PD1 antibody lenalidomide | 1 Year - 65 Years | Beijing Friendship Hospital | |
| A Phase I Clinical Study for Evaluating the Safety and Efficacy of MASCT-I in Patients With Advanced Solid Tumors | NCT03034304 | Advanced Solid ... | MASCT-I Ifosfamide PD1 antibody Adriamycin Gemcitabine Cisplatin Carboplatin | 18 Years - 70 Years | HRYZ Biotech Co. | |
| A Phase I Clinical Study for Evaluating the Safety of MASCT-I in Advanced Soild Tumor | NCT03393416 | Advanced Gastri... | MASCT-I PD1 antibody | 18 Years - 70 Years | HRYZ Biotech Co. | |
| A Phase I Clinical Study for Evaluating the Safety and Efficacy of MASCT-I in Patients With Advanced Solid Tumors | NCT03034304 | Advanced Solid ... | MASCT-I Ifosfamide PD1 antibody Adriamycin Gemcitabine Cisplatin Carboplatin | 18 Years - 70 Years | HRYZ Biotech Co. | |
| Triplex Checkpoint Inhibitors Therapy for Advanced Solid Tumors | NCT05187338 | Lung Cancer Liver Cancer Colorectal Canc... Pancreas Cancer Ovary Cancer Head and Neck C... Breast Cancer Gastric Cancer Cervical Cancer Esophageal Canc... Sarcoma | ipilimumab +pem... | 18 Years - 70 Years | Second Affiliated Hospital of Guangzhou Medical University | |
| Triplex Checkpoint Inhibitors Therapy for Advanced Solid Tumors | NCT05187338 | Lung Cancer Liver Cancer Colorectal Canc... Pancreas Cancer Ovary Cancer Head and Neck C... Breast Cancer Gastric Cancer Cervical Cancer Esophageal Canc... Sarcoma | ipilimumab +pem... | 18 Years - 70 Years | Second Affiliated Hospital of Guangzhou Medical University | |
| Phase II-III Clinical Trial of PD1 Antibody (Toripalimab), Lenvatinib and GEMOX Neoadjuvant Treatment for Resectable Intrahepatic Cholangiocarcinoma With High-risk Recurrence Factors | NCT04669496 | Intrahepatic Ch... PD1 Antibody Lenvatinib Gemox Chemother... | Neoadjuvant tre... | 18 Years - 70 Years | Shanghai Zhongshan Hospital |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
